These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36009583)

  • 1. Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model.
    Julien S; Vadysirisack D; Sayegh C; Ragunathan S; Tang Y; Briand E; Carrette M; Jean L; Zoubairi R; Gondé H; Benveniste O; Allenbach Y; Drouot L; Boyer O
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009583
    [No Abstract]   [Full Text] [Related]  

  • 2. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
    Mammen AL; Amato AA; Dimachkie MM; Chinoy H; Hussain Y; Lilleker JB; Pinal-Fernandez I; Allenbach Y; Boroojerdi B; Vanderkelen M; Delicha EM; Koendgen H; Farzaneh-Far R; Duda PW; Sayegh C; Benveniste O
    Lancet Rheumatol; 2023 Feb; 5(2):e67-e76. PubMed ID: 36923454
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Bergua C; Chiavelli H; Allenbach Y; Arouche-Delaperche L; Arnoult C; Bourdenet G; Jean L; Zoubairi R; Guerout N; Mahler M; Benveniste O; Drouot L; Boyer O
    Ann Rheum Dis; 2019 Jan; 78(1):131-139. PubMed ID: 30309969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy.
    Julien S; van der Woning B; De Ceuninck L; Briand E; Jaworski T; Roussel G; Zoubaïri R; Allenbach Y; Benveniste O; Drouot L; Boyer O
    Rheumatology (Oxford); 2023 Dec; 62(12):4006-4011. PubMed ID: 37335864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-Mediated Necrotizing Myopathy.
    Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
    Curr Rheumatol Rep; 2018 Mar; 20(4):21. PubMed ID: 29582188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy.
    Lia A; Annese T; Fornaro M; Giannini M; D'Abbicco D; Errede M; Lorusso L; Amati A; Tampoia M; Trojano M; Virgintino D; Ribatti D; Serlenga L; Iannone F; Girolamo F
    Rheumatology (Oxford); 2022 Aug; 61(8):3448-3460. PubMed ID: 34864921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
    Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
    Tang GQ; Tang Y; Dhamnaskar K; Hoarty MD; Vyasamneni R; Vadysirisack DD; Ma Z; Zhu N; Wang JG; Bu C; Cong B; Palmer E; Duda PW; Sayegh C; Ricardo A
    Front Immunol; 2023; 14():1213920. PubMed ID: 37622108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and pathological characteristics of immune mediated necrotizing myopathy].
    Yang HX; Tian XL; Jiang W; Li WL; Liu QY; Peng QL; Wang GC; Lu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):989-995. PubMed ID: 31848492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of myositis patients with isolated anti-U1 ribonucleoprotein antibody resemble immune-mediated necrotizing myopathy.
    Ge Y; Yang H; Jiang W; Tian X; Lu X; Wang G
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231181336. PubMed ID: 37465567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial seronegative immune-mediated necrotising myopathy with subsequent anti-HMGCR antibody development and response to rituximab: case report.
    Thomas R; Yeoh SA; Berkeley R; Woods A; Stevens M; Marino S; Radunovic A
    BMC Rheumatol; 2020; 4():29. PubMed ID: 32613157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
    Merlonghi G; Antonini G; Garibaldi M
    Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
    Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
    Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Rare Case of Anti-HMGCR and Anti-SRP-Positive Immune-Mediated Necrotizing Myopathy.
    Khan N; Kazmi Z
    Qatar Med J; 2022; 2022(1):6. PubMed ID: 35261909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.
    Pinal-Fernandez I; Casal-Dominguez M; Carrino JA; Lahouti AH; Basharat P; Albayda J; Paik JJ; Ahlawat S; Danoff SK; Lloyd TE; Mammen AL; Christopher-Stine L
    Ann Rheum Dis; 2017 Apr; 76(4):681-687. PubMed ID: 27651398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.
    Sharf K; Do T; Ghetie D; Choi D; Chahin N
    Arthritis Care Res (Hoboken); 2024 Nov; 76(11):1584-1592. PubMed ID: 39054727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy.
    Limaye V; Bundell C; Hollingsworth P; Rojana-Udomsart A; Mastaglia F; Blumbergs P; Lester S
    Muscle Nerve; 2015 Aug; 52(2):196-203. PubMed ID: 25521389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.
    Tiniakou E; Girgis A; Siafei T; Albayda J; Adler B; Paik JJ; Mecoli CA; Rebman A; Soloski MJ; Christopher-Stine L; Smith KN; Rosen A; Mammen AL; Darrah E
    Ann Rheum Dis; 2024 Oct; ():. PubMed ID: 39393845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Anti-HMG CoA) Myopathy With Cardiac Involvement: Presentation, Diagnosis, and Management.
    Liu L; Tessier S; Ido F; Longo S; Nanda S
    Cureus; 2022 Mar; 14(3):e23125. PubMed ID: 35425681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous involvement in anti-HMGCR positive necrotizing myopathy.
    Williams B; Horn MP; Banz Y; Feldmeyer L; Villiger PM
    J Autoimmun; 2021 Sep; 123():102691. PubMed ID: 34332436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.